

DAFTAR PUSTAKA

1. Bruni L, Barrionuevo-Rosas L, Albero G, Aldea M, Serrano B, Valencia S, Brotons M, Mena M, Cosano R, Muñoz J, Bosch FX, de Sanjosé S, Castellsagué X. ICO Information Centre on HPV and Cancer (HPV Information Centre), Human Papillomavirus And Related Diseases Report INDONESIA Version Summary Report 2015- 03-20.
2. Ellenson LH, Pirog EC. The Female Genital Tract Chapter 22. In Robbins and Cotran Pathologic Basis of Disease. 8th Eds. Editor Kumar Abbas Fausto Aster. Philadelphia: Saunders Elsevier; 2010. p. 1017-24.
3. Berek JS, editors. Berek & Novak's Gynecology. 14th Eds. New York: Lippincot Williams and Wilkins; 2007. p. 1404-50.
4. Tavassoli FA and Devilee P, edistors. Pathology & Genetics of Tumors of The Breast and Female Genital Organ. Lyon: IARC Press; 2003. p.259-71.
5. Anjani Limaye, Connor Amsy J, Huang Xiaohua et al. Comparative Analysis of Conventional Papanicolaou Test and Fluid Base Thin-Layer Method. Arch Pathol Lab Med-Vol 127, February 2003;200-4
6. Elizabeth Davey, Irwig Les, Macaskill Petra et al. Accuracy of reading liquid based cytology slides using the ThinPrep Imager compared with conventional cytology ; prospective study. *British Medical Journal* – July 2007 ; 335;31-9.
7. L.Moore, K. 2013. Anatomi Berorientasi Klinis. Edisi ke-5. S. MS & R.Astikawati, penyunting. Jakarta: Penerbit Erlangga. Hlm.418.
8. Bernard HU, Burk RD, Chen Z, van Doorslaer K, Hausen H, de Villiers EM. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. *Virology* 2010; **401**: 70–79.
9. Dunne EF, Unger ER, Sternberg M, et al. Prevalence of HPV infection among females in the United States. *JAMA* 2007;**297**: 813–19.
10. de Sanjose S, Diaz M, Castellsague X, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. *Lancet Infect Dis* 2007; **7**: 453–59.

11. Franceschi S, Herrero R, Clifford GM, et al. Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. *Int J Cancer* 2006; **119**: 2677–84.
12. Dondog B, Clifford GM, Vaccarella S, et al. Human papillomavirus infection in Ulaanbaatar, Mongolia: a population-based study. *Cancer Epidemiol Biomarkers Prev* 2008; **17**: 1731–38.
13. Zhao FH, Lewkowitz AK, Hu SY, et al. Prevalence of human papillomavirus and cervical intraepithelial neoplasia in China: a pooled analysis of 17 population-based studies. *Int J Cancer* 2012; **131**: 2929–38.
14. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. GLOBOCAN 2008. Lyon: International Agency for Research on Cancer; 2010.
15. Hammouda D, Clifford GM, Pallardy S, et al. Human papillomavirus infection in a population-based sample of women in Algiers, Algeria. *Int J Cancer* 2011; **128**: 2224–29.
16. Keita N, Clifford GM, Koulibaly M, et al. HPV infection in women with and without cervical cancer in Conakry, Guinea. *Br J Cancer* 2009; **101**: 202–08.
17. Peto J, Gilham C, Fletcher O, Matthews FE. The cervical cancer epidemic that screening has prevented in the UK. *Lancet* 2004; **364**: 249–56.
18. Castle PE, Schiffman M, Herrero R, et al. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. *J Infect Dis* 2005; **191**: 1808–16.
19. Munoz N, Mendez F, Posso H, et al. Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. *J Infect Dis* 2004; **190**: 2077–87.
20. Castle PE, Rodriguez AC, Burk RD, et al. Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study. *BMJ* 2009; **339**: b2569.
21. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. *Lancet* 2007; **370**: 890–907.

22. Maucort-Boulch D, Plummer M, Castle PE, et al. Predictors of human papillomavirus persistence among women with equivocal or mildly abnormal cytology. *Int J Cancer* 2010; **126**: 684–91.
23. Rodriguez AC, Schiffman M, Herrero R, et al. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. *J Natl Cancer Inst* 2010; **102**: 315–24.
24. IARC. Monographs on the Evaluation of Carcinogenic Risks to Humans Volume 100B: A Review of Human Carcinogens: Biological Agents. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Lyon: International Agency for Research on Cancer; 2012.
25. International Collaboration of Epidemiological Studies of Cervical Cancer. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16 573 women with cervical cancer and 35 509 women without cervical cancer from 24 epidemiological studies. *Lancet* 2007; **370**: 1609–21.
26. Guan P, Howell-Jones R, Li N, et al. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. *Int J Cancer* 2012; **131**: 2349–59.
27. Kementerian Kesehatan RI. Situasi penyakit kanker. Jakarta : Pusat Data dan Informasi. 2015; 8: 25
28. De Carvalho N, Teixeira J, Roteli-Martins CM, et al. Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine upto 7•3 years in young adult women. *Vaccine* 2010; 28: 6247–55.
29. FUTUREII StudyGroup. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. *N Engl J Med* 2007; 356: 1915–27.
30. Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. *Lancet* 2009; 374: 301–14.
31. Wheeler CM, Castellsague X, Garland SM, et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. *Lancet Oncol* 2012; 13: 100–10.

32. Einstein MH, Baron M, Levin MJ, et al. Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18–45 years. *Hum Vaccin* 2011; 7: 1359–73.
33. Arbyn M, Roelens J, Cuschieri K, et al. The APTIMA HPV assay versus the hybrid capture 2 test in triage of women with ASC-US or LSIL cervical cytology: a meta-analysis of the diagnostic accuracy. *Int J Cancer* 2013; 132: 101–08.
34. Castle PE, Stoler MH, Wright TC Jr, Sharma A, Wright TL, Behrens CM. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. *Lancet Oncol* 2011; 12: 880–90.
35. Kitchener HC, Gilham C, Sargent A, et al. A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: extended follow up in the ARTISTIC trial. *Eur J Cancer* 2011; 47: 864–71.
36. ASCUS-LSIL Triage Study (ALTS) group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. *Am J Obstet Gynecol* 2003; 188: 1383–92
37. S.J. Goldie, J.D. Goldhaber-Fiebert and G.P. Garnett, Chapter 18: Public health policy for cervical cancer prevention: The role of decision science, economic evaluation, and mathematical modeling, *Vaccine* 24(Suppl 3) (2006), S155–S163.
38. M. Arbyn, P. Sasieni, C.J. Meijer, C. Clavel, G. Koliopoulos and J. Dillner, Chapter 9: Clinical applications of HPV testing: A summary of meta-analyses, *Vaccine* 24(Suppl 3) (2006), S78–S89.
39. J. Cuzick, M.H. Mayrand, G. Ronco, P. Snijders and J. Wardle, Chapter 10: New dimensions in cervical cancer screening, *Vaccine* 24(Suppl 3) (2006), S90–S97.
40. D. Jenkins, Public Health issues related to HPV vaccination, in: *Emerging issues on HPV infections from science to practice*, J. Monsonego, ed., Karger, 2006.
41. S.J. Goldie, J.D. Goldhaber-Fiebert and G.P. Garnett, Chapter Public health policy for cervical cancer prevention: The role of decision science, economic evaluation, and mathematical modeling, *Vaccine* 24(Suppl 3) (2006), S155–S163.

42. D.M. Harper, E.L. Franco, C.M. Wheeler, A.B. Moscicki, B. Romanowski, C.M. Roteli-Martins et al., Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial, *Lancet* 367 (2006), 1247–1255.
43. P.E. Castle, D. Solomon, M. Schiffman and C.M. Wheeler, Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities, *J Natl Cancer Inst* 97 (2005), 1066–1069

**BIODATA MAHASISWA BIMBINGAN SKRIPSI FK UKI TAHUN
AKADEMIK 2016 – 2017**

Nama : Muhammad Syauqi Mirza

NIM : 1561050097

Tempat/tgl lahir : Jakarta, 27 Maret 1998

Riwayat Pendidikan

1. SLTP : Pribadi BBS Depok lulus tahun 2012
2. SLTA : SMAN 1 Depok lulus tahun 2015
3. Universitas : Universitas Kristen Indonesia 2015-2019

Judul Skripsi :

Profil Pemeriksaan sitologi serviks di MRCCC Siloam *Hospitals* Semanggi Tahun 2016